United States

  • The OnCore Technical Analyst within the Wilmot Cancer Center is the primary contact for all Cancer Center OnCore-related activities in collaboration with the OnCore Technical Analyst and teams within the Office of Clinical Research. The Technical Analyst is responsible for working with diverse levels of staff to maintain and improve the functionality and use of OnCore within the Cancer Center and assure the business strategy is driving the system use/requirements. This role serves as the “communications hub” to disseminate information to the clinical trial team members, central services teams, and senior leadership within the Cancer Center. The Technical Analyst serves a pivotal role representing the business strategy, the people, and the technology. This role has a dual reporting line to both the Cancer Center and the University Embark Team within the Office of Clinical Research

  • Position Summary: The OnCore Technical Analyst within the Office of Clinical Research is the primary contact for all OnCore-related activities in collaboration with Oncore Analysts across the institution. The Technical Analyst is responsible for working with diverse levels of staff to maintain and improve the functionality and use of OnCore and assure the business strategy is driving the system use/requirements. This role serves as the “communications hub” to disseminate information to the clinical trial team members, central services teams, and senior leadership. The Technical Analyst serves a pivotal role representing the business strategy, the people, and the technology. This role will be collaborating with other departments across the institution and report to the University Embark Team within the Office of Clinical Research.

  • The SMART IRB team has published a new paper that provides background and updates on the platform and Agreement. Excerpt from abstract: Single institutional review board (IRB) review of multisite research increased in frequency over a decade ago with a proliferation of master IRB reliance agreements supporting statewide and regional consortia and disease- and population-specific networks. Although